Actinium Pharmaceuticals to Present Innovative Radiotherapy Data at AACR 2026

Actinium Pharmaceuticals, Inc. is set to present new research affirming the preclinical potential of its radiotherapy platform for both solid tumors and acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Annual Meeting 2026. This highly anticipated event will feature two key presentations from Actinium on April 21, 2026, in San Diego, California.

The first presentation focuses on ATNM-400, a groundbreaking Ac-225 radioconjugate demonstrating broad pan-tumor efficacy in various solid tumor models. This includes efficacy in tumors resistant to existing targeted therapies. The findings suggest that ATNM-400 could be a first-in-class treatment option for major solid tumor indications.

In parallel, Actimab-A will be showcased for its mutation-agnostic efficacy in AML. The research highlights a novel transcriptional reprogramming mechanism, enhancing the responsiveness to standard AML therapies. By elucidating this mechanism, Actinium supports Actimab-A's role in improving therapeutic outcomes in AML cases.

Both presentations are part of the session titled "Radiopharmaceutical Platforms for Theranostic Precision Oncology." Details of the schedule for Actinium’s presentations are as follows:

• ATNM-400 Poster Presentation:

  ADVERTISEMENT
  • Poster Number: 5824
  • Time: April 21, 2026, from 2:00 PM to 5:00 PM PT
  • Location: Poster Section 16, Board #18

• Actimab-A Poster Presentation:

  ADVERTISEMENT
  • Poster Number: 5827
  • Time: April 21, 2026, from 2:00 PM to 5:00 PM PT
  • Location: Poster Section 16, Board #21

Sandesh Seth, Chairman and CEO of Actinium, emphasized the potential impact of these findings, noting the versatility and strength of their Ac-225 radiotherapy platform. According to Seth, these developments align with Actinium's strategy to create a differentiated pipeline that drives value and improves outcomes for patients with cancer.

Actinium Pharmaceuticals focuses on advancing innovative radiotherapies, particularly radioconjugates, to enhance patient outcomes while minimizing damage to healthy tissue. Their current pipeline includes targeted therapies for solid tumors and blood cancers such as AML, developed in collaboration with the National Cancer Institute (NCI).